A new artificial intelligence platform called Doctronic is already being used in the United States to renew prescription medications without direct physician involvement. In Utah, patients can answer questions online and receive prescription renewals for chronic conditions for about $4, with the AI system evaluating their responses and sending the prescription directly to a pharmacy. Supporters argue that automating routine medication renewals could reduce costs, improve access to care, and allow doctors to focus on more complex medical cases.
However, critics warn that the scientific evidence supporting the safety of this technology is extremely limited. The main study cited by the company behind the system is an unpublished preprint that has not undergone peer review. All authors of that study reportedly have financial ties to the company, and the underlying data has not been publicly shared for independent evaluation. Despite claims that the AI matches doctors’ treatment plans 99.2 percent of the time, that statistic comes from urgent-care scenarios rather than the chronic prescription renewals now being tested in real patients.
Medical experts also fear that AI errors could disproportionately affect vulnerable groups such as elderly patients or those with complex medical histories. Chronic conditions can change quietly over time, requiring medication adjustments that an automated system might miss. Previous healthcare AI tools — including some high-profile systems for cancer treatment recommendations and sepsis detection — were widely adopted before thorough validation and later revealed serious flaws, highlighting the risks of deploying medical AI without strong oversight.
Because of these concerns, many physicians and researchers are calling for stricter regulation before autonomous AI prescribing becomes widespread. They argue that federal regulators should treat such systems as medical devices and require transparent evidence, independent testing, and public data sharing. While AI could eventually make healthcare more efficient and accessible, experts warn that deploying it prematurely could turn a promising innovation into a public health risk.
